This is a high-margin, subscription-first daily liver and metabolic health brand for adults who drink, selling a clinically studied supplement through Shopify and Amazon. The product is rated 4.8 stars across 773+ verified reviews, customers stay on multi-month subscriptions, and operations are fully outsourced. In 20 months the company generated $5.5M in gross sales ($4.8M net revenue through September), including $3.54M in the last 12 months, with 25,000+ customers across Shopify and Amazon. Adjusted EBITDA before management compensation was $431K for the 12 months to June 2026: $255.9K of EBITDA plus $174.6K of one-off projects, ended retainers and owner items, verified line by line in a general-ledger review. The platform's $196.7K net profit covers the year to September, a different period. ✅ $107K a month in subscription MRR across 2,659 active subscriptions (Loop $83.9K, Amazon Subscribe & Save $23.6K average); more than half of September revenue came from subscription renewals, and 6-month plans collect $239 upfront ✅ 49% of 6-month and 57% of 3-month subscribers renew for another term; subscribers are worth $339 each to date and still rising, and 2026 cohorts retain like 2025 ✅ Completed 12-week pre/post study of the finished formula, run by an independent research company: 92% woke refreshed more often, 94% improved on five or more of nine outcomes, 75% had a decrease in at least one liver enzyme ✅ Exclusive on-demand inventory agreement: avoids funding large production runs, with about $31K of stock on hand ✅ Exclusive rights to a patented ingredient, 1,000+ clinician recommendations, a first direct clinic order (October 2026) and an at-home liver blood test kit ✅ Built by founders with prior exits and advised by operators behind notable consumer-health and beverage-brand exits ✅ Growth upside: the new study claims in ads, retail and practitioner channels, Amazon, 11,500+ one-time buyers to convert, new SKUs and international expansion
Put the completed study's results (final October 2026) into ads and landing pages. Take the product into retail and practitioner channels, which the study and 1,000+ recommending clinicians suit; the first direct clinic order came in October 2026. Use the at-home liver blood test kit as a front-end offer and retention tool. Add study claims to Amazon. Launch the exclusive ingredient as an upgrade or new SKU. Convert 11,500+ one-time buyers to subscription. Expand to Canada, the UK, Australia and Europe.